Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gains from Sales and Divestitures (2024)

Insight Molecular Diagnostics' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $20000.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 400.0% year-over-year to $20000.0; the TTM value through Sep 2025 reached $20000.0, up 400.0%, while the annual FY2022 figure was -$25.9 million, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $20000.0 at Insight Molecular Diagnostics, up from $18000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $20000.0 in Q3 2025 and bottomed at $4000.0 in Q3 2024.